Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity
Maikel Izquierdo,De Lin,Sandra O’Neill,Lauren A. Webster,Christy Paterson,John Thomas,Mirtha Elisa Aguado,Enrique Colina Araújo,Daniel Alpízar-Pedraza,Halimatu Joji,Lorna MacLean,Anthony Hope,David W. Gray,Martin Zoltner,Mark C. Field,Jorge González-Bacerio,Manu De Rycker
DOI: https://doi.org/10.1371/journal.pntd.0011956
2024-02-16
PLoS Neglected Tropical Diseases
Abstract:Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and leads to ~10,000 deaths each year. Nifurtimox and benznidazole are the only two drugs available but have significant adverse effects and limited efficacy. New chemotherapeutic agents are urgently required. Here we identified inhibitors of the acidic M17 leucyl-aminopeptidase from T . cruzi (LAPTc) that show promise as novel starting points for Chagas disease drug discovery. A RapidFire-MS screen with a protease-focused compound library identified novel LAPTc inhibitors. Twenty-eight hits were progressed to the dose-response studies, from which 12 molecules inhibited LAPTc with IC 50 < 34 μM. Of these, compound 4 was the most potent hit and mode of inhibition studies indicate that compound 4 is a competitive LAPTc inhibitor, with K i 0.27 μM. Compound 4 is selective with respect to human LAP3, showing a selectivity index of >500. Compound 4 exhibited sub-micromolar activity against intracellular T . cruzi amastigotes, and while the selectivity-window against the host cells was narrow, no toxicity was observed for un-infected HepG2 cells. In silico modelling of the LAPTc-compound 4 interaction is consistent with the competitive mode of inhibition. Molecular dynamics simulations reproduce the experimental binding strength (-8.95 kcal/mol), and indicate a binding mode based mainly on hydrophobic interactions with active site residues without metal cation coordination. Our data indicates that these new LAPTc inhibitors should be considered for further development as antiparasitic agents for the treatment of Chagas disease. Trypanosoma cruzi is a single cell eukaryotic parasite that infects humans and animals. Infection can result in Chagas disease, a debilitating chronic disease that frequently affects the heart. The major downside of the current treatments is their side-effects, which frequently prevent patients from completing their treatment course. New, safer medicines are therefore urgently needed. Here we sought to enable the development of new medicines by identifying inhibitors of a key parasite enzyme; acidic M17 leucyl-aminopeptidase (LAPTc). We identified 28 LAPTc inhibitors, among more than 3000 compounds tested. The most potent inhibitor, compound 4, inhibited parasite growth and did not inhibit the equivalent human aminopeptidase. Using computational tools, we predicted how this compound binds to the enzyme. Our results indicate that the LAPTc inhibitors could be considered for further development as antiparasitic agents for the treatment of Chagas disease.
tropical medicine,parasitology